Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression

• Published in: Science translational medicine Vol. 16; no. 734; p. eade7347
• Main Authors: Bai, Lan, Qu, Weiyi, Cheng, Xu, Yang, Hailong, Huang, Yong-Ping, Wang, Zhenya, Han, Cuijuan, Tian, Rui-Feng, Hu, Fengjiao, Yang, Ling, Tian, Song, Tian, Han, Cai, Zhiwei, Wan, Juan, Jiang, Jingwei, Fu, Jiajun, Zhou, Junjie, Hu, Yufeng, Ma, Tengfei, Zhang, Xin, Ji, Yan-Xiao, Cai, Jingjing, She, Zhi-Gang, Wang, Yibin, Zhang, Peng, Huang, Lingli, Li, Hongliang, Zhang, Xiao-Jing
• Format: Journal Article
• Language: English
• Published: United States 14.02.2024
• Subjects: Animals; Gene Expression Profiling; Hepatocytes - metabolism; Intracellular Signaling Peptides and Proteins - metabolism; Liver - metabolism; Mice; Mitogen-Activated Protein Kinases - metabolism; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - prevention & control; Signal Transduction - physiology
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.ade7347

Nonalcoholic fatty liver (NAFL) remains relatively benign, but high-risk to end-stage liver diseases become highly prevalent when it progresses into nonalcoholic steatohepatitis (NASH). Our current understanding of the development of NAFL to NASH remains insufficient. In this study, we revealed MAP kinase (MAPK) activation as the most notable molecular signature associated with NASH progression across multiple species. Furthermore, we identified suppressor of IKKε ( ) as a conserved and potent negative controller of MAPK activation. Hepatocyte-specific overexpression of prevented NASH progression in diet- and toxin-induced mouse NASH models. Mechanistically, SIKE directly interacted with TGF-β-activated kinase 1 (TAK1) and TAK1-binding protein 2 (TAB2) to interrupt their binding and subsequent TAK1-MAPK signaling activation. We found that indobufen markedly up-regulated expression and effectively improved NASH features in mice and macaques. These findings identify SIKE as a MAPK suppressor that prevents NASH progression and provide proof-of-concept evidence for targeting the SIKE-TAK1 axis as a potential NASH therapy.